RLMD
Income statement / Annual
Last year (2023), Relmada Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Relmada Therapeutics, Inc.'s net income was -$98.79 M.
See Relmada Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Cost of Revenue |
$0.00 |
$0.00 |
$1,258.00 |
$3,752.00 |
$0.00 |
$4,870.00 |
$2,627.00 |
$85,271.00 |
$54,819.00 |
$9,256.00 |
Gross Profit |
$0.00 |
$0.00 |
-$1,258.00 |
-$3,752.00 |
$0.00 |
-$4,870.00 |
-$2,627.00 |
-$85,271.00 |
-$54,819.00 |
-$9,256.00 |
Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Research and Development
Expenses |
$54.81 M
|
$113.32 M
|
$90.62 M
|
$35.97 M
|
$7.86 M
|
$7.02 M
|
$2.94 M
|
$1.29 M
|
$6.21 M
|
$7.87 M
|
General & Administrative
Expenses |
$48.89 M
|
$47.93 M
|
$35.08 M
|
$24.87 M
|
$7.25 M
|
$5.70 M
|
$3.97 M
|
$5.93 M
|
$10.01 M
|
$9.23 M
|
Selling & Marketing
Expenses |
$12.31 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$48.89 M
|
$47.93 M
|
$35.08 M
|
$24.87 M
|
$7.25 M
|
$5.70 M
|
$3.97 M
|
$5.93 M
|
$10.01 M
|
$9.23 M
|
Other Expenses |
$0.00 |
$6.35 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$2,350.00 |
$216,212.00 |
$130,269.00 |
$0.00 |
Operating Expenses |
$103.70 M |
$161.25 M |
$125.70 M |
$60.84 M |
$15.11 M |
$12.73 M |
$6.92 M |
$7.22 M |
$16.22 M |
$17.10 M |
Cost And Expenses |
$103.70 M |
$161.25 M |
$125.70 M |
$60.84 M |
$15.11 M |
$12.73 M |
$6.92 M |
$7.22 M |
$16.22 M |
$17.10 M |
Interest Income |
$0.00 |
$2.66 M |
$1.20 M |
$1.40 M |
$104.11 |
-$761,038.00 |
-$1.34 M |
-$550.00 |
$1,747.00 |
$10,883.00 |
Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.34 M |
$0.00 |
$0.00 |
$4,922.00 |
Depreciation &
Amortization |
$103.70 M
|
$2,000.00
|
$1,258.00
|
$3,752.00
|
$4,363.00
|
$4,870.00
|
$2,627.00
|
$85,271.00
|
$54,819.00
|
$9,256.00
|
EBITDA |
-$103.70 M
|
-$156.44 M
|
-$124.45 M
|
-$60.82 M
|
-$15.10 M
|
-$8.89 M
|
-$6.21 M
|
-$7.85 M
|
-$29.27 M
|
-$13.38 M
|
EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other
Income/Expenses Net |
$4.91 M
|
$1.55 M
|
-$1.25 M
|
-$16,946.00
|
$104,112.00
|
-$3.83 M
|
-$706,551.00
|
$932,862.00
|
$13.24 M
|
-$3.71 M
|
Income Before Tax |
-$98.79 M |
-$157.04 M |
-$125.75 M |
-$59.46 M |
-$15.01 M |
-$17.32 M |
-$8.96 M |
-$6.29 M |
-$2.97 M |
-$20.80 M |
Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$103,702.00 |
-$2.66 M |
$48,317.00 |
-$1.38 M |
-$1.00 |
$4.59 M |
$2.05 M |
-$716,100.00 |
-$13.11 M |
$3.70 M |
Net Income |
-$98.79 M |
-$157.04 M |
-$125.75 M |
-$59.46 M |
-$15.01 M |
-$17.32 M |
-$8.96 M |
-$6.29 M |
-$2.97 M |
-$20.80 M |
Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
EPS |
-3.28 |
-5.3 |
-7.16 |
-3.81 |
-1.63 |
-2.74 |
-2.86 |
-2.08 |
-1.03 |
-8.37 |
EPS Diluted |
-3.28 |
-5.3 |
-7.16 |
-3.81 |
-1.63 |
-2.74 |
-2.86 |
-2.08 |
-1.03 |
-8.37 |
Weighted Average Shares
Out |
$30.10 M
|
$29.63 M
|
$17.55 M
|
$15.59 M
|
$9.23 M
|
$6.31 M
|
$3.14 M
|
$3.02 M
|
$2.90 M
|
$2.49 M
|
Weighted Average Shares
Out Diluted |
$30.10 M
|
$29.63 M
|
$17.55 M
|
$15.59 M
|
$9.23 M
|
$6.31 M
|
$3.14 M
|
$3.02 M
|
$2.90 M
|
$2.49 M
|
Link |
|
|
|
|
|
|
|
|
|
|